[The effect of moxisylyte hydrochloride in the symptomatic treatment of benign prostatic hyperplasia].
The clinical effectiveness of moxisylyte hydrochloride (Moxyl, Fuji Rebio), a selective alpha 1-adrenoceptor blocking agent, was investigated in patients with symptomatic benign prostatic hyperplasia. Moxisylyte hydrochloride was administered at the dose of 90 mg per day orally for four weeks. Residual urine sensation was improved in 9 out of 17 cases (53%), retarded urination in 14 out of 19 (74%), prolonged urination in 12 out of 19 (63%), weak stream in 14 out of 21 (67%) and strained voiding in 11 out of 19 cases (58%). Residual urine volume and residual urine ratio were decreased in 14 out of 21 cases (67%), maximum urine flow rate was increased in 14 out of 21 (67%) and mean flow rate was increased in 15 out of 21 cases (71%). There was, however, no statistical significance between pre- and post drug administration in objective parameters. Our open trial showed that the subjective efficacy of moxisylyte hydrochloride was 82% (18/22 cases), the objective one was 59% (13/22 cases) and overall efficacy was 77%. Side effects were observed in four of all subjects (18.2%), and drug administration had to be ceased in only one of these patients due to mild dizziness. Other side effects were mild nausea, headache and chest discomfort. Decrease in blood pressure was not seen in all but one case.
Izumi
H
H
Department of Urology, School of Medicine, Kitasato University.
Kudo
S
S
Fuino
A
A
Yokoyama
E
E
Ishibashi
A
A
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D013948:Moxisylyte / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination; D014563:Urodynamics
D000317:Adrenergic alpha-Antagonists; D013948:Moxisylyte